Paul William Manley

机构：Novartis (Switzerland), Auckland City Hospital, Novartis Foundation · ORCID：0000-0002-9722-7863

发表论文 283 篇 · 总被引 18517 次 · h-index 64

代表论文

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (2023 · The Lancet · 被引 301)
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023 · The Lancet · 被引 226)
Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial (2023 · The Lancet · 被引 87)
Clinical Pharmacology of Asciminib: A Review (2024 · Clinical Pharmacokinetics · 被引 28)
Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”** (2022 · Angewandte Chemie International Edition · 被引 7)
Graft Loss in Pediatric and Young Adult Kidney Transplantation in New Zealand: Who Is at Greatest Risk and When? (2024 · Pediatric Transplantation · 被引 2)